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ABSTRACT 
Many countries have national guidelines on the prevention and control of MRSA 
which are similar in approach.  The evidence base for many recommendations is 
variable and often in the drafting of such guidelines, the evidence is either not 
analysed or specifically reviewed. Guidelines usually recommend screening and early 
detection, hand hygiene, patient isolation or cohorting, and decolonisation.  While 
many components of a prevention and control programme appear self-evident, e.g. 
patient isolation, the scientific base underpinning these is poor and scientifically more 
rigorous studies are required.  Nonetheless, where measures, based on what evidence 
there is and on common sense, are implemented and where the necessary resources 
are provided, MRSA can be controlled.  In the Netherlands and in other low 
prevalence countries, these measures have largely maintained healthcare facilities 
MRSA free.  In MRSA endemic countries such as Spain and Ireland, national 
guidelines are often not fully implemented due to apparent inadequate resources or a 
lack of will.  However, recent studies from France and Australia, demonstrate what is 
possible in high prevalence countries when best practice is effectively implemented, 
with potentially major benefits for patients, the respective health services and society. 
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Background 
Methicillin-resistant Staphylococcus aureus (MRSA) is a well recognised cause of 
healthcare-associated infection (HCAI) and is increasingly now seen outside acute 
healthcare facilities in some countries.  Its clinical impact, in terms of morbidity and 
mortality is well recognised.  In an observational study of 198 intensive care units in 
24 European countries, Staphylococcus aureus was the most common pathogen 
implicated in sepsis and 14% of isolates were MRSA [1].  MRSA bloodstream 
infection is associated with significant mortality.  In a meta-analysis of studies of 
bloodstream infection due to methicillin-resistance and methicillin-susceptible S. 
aureus, there was a significant association between death and methicillin resistance 
[2]. 
 
Given the prevalence of MRSA in many European countries, its clinical impact, and 
the concern of patients, the public and many health care staff, there is widespread 
recognition of the need for a multi-disciplinary approach to prevention and control.  
However, the prevalence of MRSA varies considerably amongst European countries 
and from a review of national guidelines, there are some variations in the strategies 
adopted and in the effectiveness of their implementation.  
 
Guidelines and recommendations 
While many institutions and professional groups have attempted to address the spread 
and control of MRSA, the implementation of evidence-based guidelines has been 
somewhat ad hoc.  For example, the European Practice Database has collected data on 
renal practice in different European countries and found that 1.3% of haemodialysis 
patients are MRSA positive [3].  However, in Greece, Italy, England and Belgium, 
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over 50% of centres screen for MRSA compared with less than 10% of centres in 
Slovakia, Norway, the Czech Republic and Scotland [3].   
 
Guidelines from Germany, New Zealand, North America, the Netherlands, Ireland 
and the UK have recently been reviewed [4].  While many of these guidelines share 
common themes, e.g. the importance of early identification of MRSA, patient 
isolation or cohorting, hand hygiene, etc., the process by which these guidelines was 
developed varies somewhat in terms of the analysis of the evidence base.  In addition, 
given the apparent similarity of many aspects in the approach between the various 
countries, it is somewhat surprising that there is such a range of prevalence between 
countries, e.g. the Netherlands (low prevalence) and Spain and Ireland (high 
prevalence).  When reviewing the literature on interventions to control and prevent 
MRSA, there is often an absence of detail about the infrastructure in which outbreaks 
or studies occur, and the degree to which there is full support from local 
organisational and national agencies [5]. A recent assessment of antimicrobial drug 
use and infection control practices in European hospitals confirms this as it showed 
that there were higher levels of MRSA where there were problems in implementing 
isolation policies and lower rates of MRSA were associated with the use of alcohol-
based hand hygiene [6]. 
 
The evidence base for MRSA guidelines  
Much of what is included in local or national recommendations on the prevention and 
control of MRSA is both logical and self-evident and the effectiveness of these 
interventions when implemented can be seen in those countries where the prevalence 
of MRSA infection is low, such as in the Netherlands.  Nonetheless, it is often 
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difficult to determine from the literature the degree to which individual specific 
components of a strategy are effective, and where the emphasis is best placed. 
 
In a systematic review of the published literature between 1996 and 2004, well-
conducted evaluations reporting the economic benefits arising from infection 
prevention and control interventions on MRSA were lacking and for four of five 
specific interventions, i.e. screening patients before or on admission, the use of 
surveillance data, isolation/cohorting and decolonisation, the conclusions were at best 
tentative and far from conclusive, not withstanding the logic associated with each of 
them [7].   
 
Patient isolation is considered one of the most important interventions in reducing the 
transmissibility of healthcare infection.   However, a recent review of 46 studies 
indicated that there were major methodological weaknesses and inadequate reporting 
in much of the published research [8].  There is a need for greater rigor in the quality 
of publications that deal with the control and prevention of HCAI.  Recently, a set of 
standards or guidelines has been published to enable researchers and others in the 
field to check the validity of their studies and results against a check list [9].  This 
approach should promote better studies and enable us to have more valid scientific 
evidence for much of what is currently practiced and implemented in the control and 
prevention of MRSA.   
 
Current Practice 
While national and local guidelines are often disseminated, it is essential to ascertain 
whether guidelines are partially or fully implemented when trying to understand 
prevalence data.  In a survey of 36 UK adult cardiac surgical units during 2001, it was 
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found that only 65% of units screened all patients for MRSA and 45% regularly 
screened long-term patients remaining in the unit [10], even though the national 
guidelines at the time identified that cardiothoracic units were high-risk areas for 
MRSA and recommended admission screening [11].  The authors concluded that 
there was wide variation in practice within the UK for cardiac surgical units, but that 
there needed to be some rationalisation of pre-operative screening and the use of 
prophylactic antibiotics [10].  In Ireland, a follow up review of the implementation of 
recent national guidelines found that 43 of 49 acute hospitals experienced barriers to 
their full implementation and in four hospitals there was no education programme on 
hand hygiene [12]. 
 
A multi-disciplinary approach that included education, improved ward and theatre 
hygiene, pre-admission, admission and weekly MRSA screening, isolation and 
decolonisation, largely based on national guidelines [11], resulted in a significant fall 
in both the unit-acquisition of MRSA and bloodstream MRSA infections, in a London 
cardiothoracic unit [13].  Also, in a survey of 207 general intensive care units in the 
UK, there was a marked variation in practice, including the finding that 75% of units 
screened patients on admission, isolation cubicles were not present in 10% of units, 
and 24% of units did not routinely isolate patients with MRSA [14]. These results 
suggest that up to now in the UK, national guidelines could not or were not being 
implemented.  Although a recent UK study has suggested that isolation in the 
intensive care unit may not be as effective as originally thought [15], there were 
confounding variables in that study that would have offset the effectiveness of 
isolation, e.g. sub-optimal hand hygiene and admission screening for MRSA, many of 
which were discussed in the accompanying editorial [16]. 
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In the Netherlands, there is an impressive low prevalence of MRSA in hospitals.  In a 
Dutch study that assessed the prevalence of MRSA amongst patients without risk 
factors for MRSA carriage at the time of admission to hospital, only three MRSA 
carriers were identified, representing 0.3% of the survey population [17].  When 
outbreaks of MRSA do occur in the Netherlands, it is clear that considerable efforts 
are made, with the accompanying resources, to ensure that not only is any initial  
MRSA spread controlled, but also that MRSA is eradicated, illustrating the 
effectiveness of the “search and destroy” approach in low prevalence countries.   
 
During a recent outbreak in a 700-bed Dutch hospital, additional laboratory resources 
were provided, the aggressive screening of patient and staff contacts was undertaken, 
and additional infection prevention and control staff were made available, to assist in 
outbreak management [18].  Therefore, although this represented an epidemic in a 
country with low MRSA prevalence rates, compared with endemic MRSA in many 
other European countries, best practice consistent with national guidelines 
(http://www.wip.nl/UK/free_content/Richtlijnen/MRSA(1).pdf)  was implemented 
and the necessary resources, including finance, space and personnel, were provided. 
This consistent and comprehensive approach ensured that the outbreak was brought to 
an end.   
 
While there are considerable costs associated with such aggressive measures, this 
appears to be cost effective.  Over a 10 year period (1991-2000), the aggressive 
implementation of MRSA control measures in the Netherlands resulted in 2,265 lost 
hospitalisation days but this “search and destroy” approach resulted in the likely 
prevention of 520,000 infections per year and the cost of the policy was €280,000 per 
year [19].   
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France has had a relatively high national prevalence of MRSA but efforts have been 
under way nationally and locally in recent years to improve this situation with 
encouraging results.  In a programme that involved three intensive care units over 
seven years and which consisted of screening and contact precautions, but not routine 
MRSA decolonisation, there was a reduction of MRSA acquired in the intensive care 
unit from 7% to 2.8% [20].  Similarly, in Australia, a series of interventions in a 35-
bed intensive care unit resulted in a decline in the number of MRSA cases in the ICU 
as well as throughout the hospital [21].  Finally, in the United States of America, 
screening policies for MRSA vary between ICUs.  However, two recent surveys have 
highlighted the importance of routine ICU surveillance to establish the true 
prevalence of MRSA (both colonisation and infection) and that this is an important 
component in reducing MRSA rates, including MRSA bloodstream infection [22,23].   
Therefore the implementation of recommended measures, whether they be enhanced 
screening for MRSA, improved hand hygiene, isolation/cohorting, is effective in 
reducing rates or minimising transmission. 
 
Recent and future developments 
The finding that in general, national guidelines are not dissimilar in terms of their 
strategic approach to the prevention and control of MRSA, suggests that the 
difference between countries relates partly to the resources provided for HCAI 
prevention and control, as well as the priority that is given to such quality measures, 
i.e. the culture of the healthcare environment.  While there are some indications that 
in previously high prevalence European countries such as France and Slovenia, 
improvements have been made 
(http://www.rivm.nl/earss/Images/EARSS%202006%20Def_tcm61-44176.pdf), there 
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is often discussion in low prevalence countries on the need to continue to implement 
aggressive control measures as these are perceived as quite costly.  A recent review of 
current policy in the Netherlands in 2006, which was requested by the Dutch 
Department of Health, concluded that the current aggressive, “search and destroy” 
approach should be continued because it results in significantly fewer infections and 
reduced antibiotic costs, than would otherwise be the case if it was to be abandoned 
(http://www.gr.nl/pdf.php?ID=1461&p=1).   
 
Guidelines need to be tailored to the specific clinical circumstances, without 
compromising the essential principles underpinning them, but there needs to be buy-
in from the relevant healthcare professionals.  In Canada, a working group has 
provided clear and sensible advice for the specific management of outbreaks of 
MRSA in neonatal intensive care units [24].  This needs to be accompanied by greater 
consistency in approach, as suggested by another recent Canadian survey.  Although 
96% of hospitals screened for MRSA, only 21% conducted regular prevalence 
surveys, 82% undertook decolonisation, and 75% had restrictive antibiotic prescribing 
[25].  In addition, many countries have recognised the need for guidelines on MRSA 
in the community to reflect the emergence of true community-acquired strains and the 
phenomenon of MRSA in healthcare facilities such as acute hospitals ‘spilling over’ 
in to community units and primary care [26]. 
 
The future may result in greater consistency in policies between both institutions and 
countries, with greater commitment to their implementation by national and other 
bodies, driven by patient expectations and demands.  However, this will require 
appropriate governance structures to ensure that a multi-disciplinary approach can be 
implemented. All healthcare workers must realise that the prevention and control of 
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HCAI is everybody’s responsibility.  However, this must be accompanied by suitable 
educational programmes.  Over two-thirds of surgical trainees in the UK were 
unaware of policies for the transfer of MRSA-positive patients and 62% were 
misinformed about the prevalence of MRSA bloodstream infections [27]. This 
implies that apart from an educational deficit, there may remain a perception that the 
prevention and control of infection is largely the responsibility of specialist personnel 
whose responsibility it is to minimise all infections including those caused by MRSA. 
 
The successful implementation of healthcare bundles to reduce central line-associated 
infections [28] suggest that it is possible to reduce HCAI, including MRSA to an 
irreducible minimum, but this requires a major change in attitude.  However, such 
change will result in improvements in the quality and safety of patient care, and is 
likely to have significant cost benefits for the health services and society.  In 
conclusion, guidelines on the prevention and control of MRSA are effective if they 
are implemented and if they are resourced.  In many European countries this requires 
a major change in culture that prioritises the quality and safety of patient care. 
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